A PHASE 1 OPEN-LABEL, MULTIREGIONAL, MULTICENTER, BASKET STUDY EVALUATING THE SAFETY AND EFFICACY OF KITE-363, AN AUTOLOGOUS ANTI-CD19/CD20 CAR T-CELL THERAPY IN PARTICIPANTS WITH REFRACTORY AUTOIMMUNE DISEASES
- Registry ID
- KT-US-720-0203
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- KITEPHARMA INC
- Start date
- 2026-08-07
- Last update
- 2025-06-27
Conditions
Related clinical trials
- A PHASE 2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF ORAL BREPOCITINIB IN ADULTS WITH LICHEN PLANOPILARIS
- A PHASE 1 STUDY EVALUATING THE SAFETY AND PRELIMINARY EFFICACY OF ALLO-
329, A DUAL ANTI-CD19 / ANTI-CD70 ALLOGENEIC CAR T CELL PRODUCT IN
AUTOIMMUNE DISEASE (RESOLUTION)
- A RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO DEMONSTRATE THE COMPARABILITY
OF PHARMACOKINETICS OF SUBCUTANEOUS IANALUMAB BETWEEN 2ML AUTOINJECTOR/2ML PRE-FILLED SYRINGE WITH 1 ML PRE-FILLED SYRINGE IN ADULT
PARTICIPANTS WITH AUTOIMMUNE DISEASE
- PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)
- A THREE-PERIOD MULTICENTER STUDY, WITH A RANDOMIZED WITHDRAWAL, DOUBLE-BLINDED, PLACEBO-CONTROLLED DESIGN TO EVALUATE THE CLINICAL EFFICACY, SAFETY AND TOLERABILITY OF MAS825 IN PATIENTS WITH MONOGENIC IL-18 DRIVEN AUTOINFLAMMATORY DISEASES, INCLUDING NLRC4-GOF, XIAP DEFICIENCY, OR CDC42 MUTATIONS
- A PHASE IB STUDY OF NIVOLUMAB IN PATIENTS WITH AUTOIMMUNE DISORDERS AND ADVANCED MALIGNANCIES (AIM-NIVO)
View on source registry